Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary endpoint is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin (C) and paclitaxel (P) compared to placebo with C/P in subjects with a BRCA1 and/or BRCA2 Mutation and in Her-2 Negative Metastatic or Locally Advanced Unresectable Breast Cancer
Critère d'inclusion
- HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated mutation (BRCA1 and BRCA2) Breast Cancer